GEHC GE HealthCare Technologies Inc.

USD 67.08 +2.19 ( +3.37%)
Icon

GE HealthCare Technologies Inc. (GEHC) Financial Statements

COMMON STOCK | Health Information Services | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 67.08

+2.19 (+3.37%)

USD 28.76B

6.56M

USD 102.00(+52.06%)

USD 99.50 (+48.33%)

Icon

GEHC

GE HealthCare Technologies Inc. (USD)
COMMON STOCK | NSD
USD 67.08
+2.19 ( +3.37%)

GE HealthCare Technologies Inc. (GEHC) Annual Income Statement (USD)

GEHC Quarterly Financials (USD)

Frequently Asked Questions About GE HealthCare Technologies Inc. (GEHC) Stock

GE HealthCare Technologies Inc.'s (GEHC) last reported annual revenue was USD 19.67 Billion.

GE HealthCare Technologies Inc.'s (GEHC) annual revenue growth rate based on the revenue reported in the past 5 years is : 3.41%

GE HealthCare Technologies Inc.'s(GEHC) is profitable as of its last reported annual financials.

The net profit margin for GE HealthCare Technologies Inc.'s(GEHC) from its laster reported year is 10.13%

The return on equity (ROE) for GE HealthCare Technologies Inc.'s(GEHC) from its last reported annual financials is : 25.69%

The return on assets (ROA) for GE HealthCare Technologies Inc.'s(GEHC) from its last reported annual financials is : 5.77%

The return on invested capital (ROIC) for GE HealthCare Technologies Inc.'s(GEHC) from its last reported annual financials is : 12.33%

The Debt to Equity ratio for GE HealthCare Technologies Inc.'s(GEHC) from its last reported annual financials is : 88.20%

The dividend yield for GE HealthCare Technologies Inc.'s(GEHC) from its laster reported year is 0.23%

GE HealthCare Technologies Inc.'s(GEHC) has negative cash flow as of its last reported annual financials.

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...